Benjamin T Ristau1, Marc C Smaldone2. 1. Urologic Oncology, Division of Urology, UConn Health, 263 Farmington Avenue, MC-8036, Farmington, CT, 06030, USA. Benristaumd@gmail.com. 2. Division of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.
Abstract
PURPOSE OF REVIEW: Bladder cancer care is costly due to long surveillance periods for non-muscle-invasive bladder cancer (NMIBC) and comorbidities associated with the surgical treatment of muscle-invasive bladder cancer (MIBC). We reviewed current evidence-based practices and propose quality metrics for NMIBC and MIBC. RECENT FINDINGS: For patients with NMIBC, we propose four categories of candidate quality metrics: (1) appropriate use of imaging, (2) re-staging transurethral resection of bladder tumor, (3) perioperative intravesical chemotherapy, and (4) induction and maintenance BCG in high-risk NMIBC. For patients with MIBC, we propose eight candidate quality measures: (1) neoadjuvant chemotherapy, (2) multidisciplinary consultation, (3) urinary diversion teaching, (4) appropriate perioperative antibiotics, (5) venous thromboembolic prophylaxis, (6) lymphadenectomy, (7) monitoring of complications, and (8) inclusion of enhanced recovery after surgery protocols. Marked variation in evidence-based practice exists among patients with bladder cancer and represents opportunity for quality improvement. Regional and national physician-led collaboratives may be the best vehicle to achieve quality improvement in bladder cancer.
PURPOSE OF REVIEW: Bladder cancer care is costly due to long surveillance periods for non-muscle-invasive bladder cancer (NMIBC) and comorbidities associated with the surgical treatment of muscle-invasive bladder cancer (MIBC). We reviewed current evidence-based practices and propose quality metrics for NMIBC and MIBC. RECENT FINDINGS: For patients with NMIBC, we propose four categories of candidate quality metrics: (1) appropriate use of imaging, (2) re-staging transurethral resection of bladder tumor, (3) perioperative intravesical chemotherapy, and (4) induction and maintenance BCG in high-risk NMIBC. For patients with MIBC, we propose eight candidate quality measures: (1) neoadjuvant chemotherapy, (2) multidisciplinary consultation, (3) urinary diversion teaching, (4) appropriate perioperative antibiotics, (5) venous thromboembolic prophylaxis, (6) lymphadenectomy, (7) monitoring of complications, and (8) inclusion of enhanced recovery after surgery protocols. Marked variation in evidence-based practice exists among patients with bladder cancer and represents opportunity for quality improvement. Regional and national physician-led collaboratives may be the best vehicle to achieve quality improvement in bladder cancer.
Authors: Kari A O Tikkinen; Samantha Craigie; Arnav Agarwal; Philippe D Violette; Giacomo Novara; Rufus Cartwright; Richard Naspro; Reed A C Siemieniuk; Bassel Ali; Leyla Eryuzlu; Johanna Geraci; Judi Winkup; Daniel Yoo; Michael K Gould; Per Morten Sandset; Gordon H Guyatt Journal: Eur Urol Date: 2017-03-23 Impact factor: 20.096
Authors: Anthony T Corcoran; Elizabeth Handorf; Daniel Canter; Jeffrey J Tomaszewski; Justin E Bekelman; Simon P Kim; Robert G Uzzo; Alexander Kutikov; Marc C Smaldone Journal: BJU Int Date: 2014-07-14 Impact factor: 5.588
Authors: Peter C Albertsen; James A Hanley; George H Barrows; David F Penson; Pam D H Kowalczyk; M Melinda Sanders; Judith Fine Journal: J Natl Cancer Inst Date: 2005-09-07 Impact factor: 13.506
Authors: Patrick Hurley; Apoorv Dhir; Yuqing Gao; Brian Drabik; Kenneth Lim; Jon Curry; Paul R Womble; Susan M Linsell; Andrew Brachulis; Donald W Sexton; Khurshid R Ghani; Brian T Denton; David C Miller; James E Montie Journal: J Urol Date: 2016-11-23 Impact factor: 7.450
Authors: Richard J Sylvester; Willem Oosterlinck; Sten Holmang; Matthew R Sydes; Alison Birtle; Sigurdur Gudjonsson; Cosimo De Nunzio; Kikuo Okamura; Eero Kaasinen; Eduardo Solsona; Bedeir Ali-El-Dein; Can Ali Tatar; Brant A Inman; James N'Dow; Jorg R Oddens; Marek Babjuk Journal: Eur Urol Date: 2015-06-16 Impact factor: 20.096
Authors: Karim Chamie; Christopher S Saigal; Julie Lai; Jan M Hanley; Claude M Setodji; Badrinath R Konety; Mark S Litwin Journal: Cancer Date: 2011-07-11 Impact factor: 6.860
Authors: Ted A Skolarus; Zaojun Ye; Jeffrey S Montgomery; Alon Z Weizer; Khaled S Hafez; Cheryl T Lee; David C Miller; David P Wood; James E Montie; Brent K Hollenbeck Journal: Urology Date: 2011-10-11 Impact factor: 2.649